Biotech Values

[biomaven0]

>AMRN

fairly priced and slightly overpriced

I've been consistently skeptical of AMRN, and I remain so today. I don't think they will get NCE status, and without it they won't get a partner. Further, with Vescapa patent expiration not that far off, I just don't see insurers paying for AMRN's drug without the patient having first tried Vescapa. Finally, with good reason, doctors are increasingly skeptical of biomarker-based results in the cardiac space - they want to see outcomes studies.

Peter